Dojolvi (TriHEPtanoin) Patent Expiration, LOE Window & CMS Spending

Dojolvi (TriHEPtanoin) by Ultragenyx Pharmaceutical: FDA Orange Book LOE 2034-11-14, 0 AB generics, $25.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUltragenyx Pharmaceutical
FDA Application & PathwayN213687 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-11-14
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$25.4M
2024 Medicare Part D Spend$2.9M
2024 Medicaid Spend$22.5M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Ultragenyx Pharmaceutical across sibling Meru public-data platforms.